Volatile Anesthetics to Reduce Mortality in Cardiac Surgery (MYRIAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02105610|
Recruitment Status : Completed
First Posted : April 7, 2014
Last Update Posted : April 2, 2019
There is initial evidence that the choice of anesthesia can influence survival in the specific setting of coronary artery bypass grafting surgery (CABG).
A recent international consensus conference included volatile agents among the few drugs/techniques/strategies that might reduce perioperative mortality in cardiac surgery and that should be further studied. Volatile anesthetics (desflurane, isoflurane and sevoflurane) have non-anesthetic pharmacological characteristics that confer cardiac protection when compared to Total IntraVenous Anesthesia (TIVA). Several randomized controlled studies were summarized in a meta-analysis that documented a reduction in perioperative cardiac troponin release and mortality in patients receiving volatile anesthetics when compared to patients receiving a TIVA. There are four published studies (Bignami et al. 2009) (De Hert et al. 2009) (Jackobsen et al. 2007) (Landoni et al. 2007) suggesting that these benefits can translate into a reduced mortality rate in patients receiving volatile agents. The level of evidence for these four studies is not high (one meta-regression, one underpowered randomized controlled study, one retrospective study and one meta-analysis of small randomized studies) and there is need for a large multicentre randomized controlled study to confirm these findings, as suggested by the international consensus conference on this topic published in 2011 (Landoni et al 2011).
The purpose is to provide a large multicentre controlled randomized trial to demonstrate that volatile anesthetics can reduce 1 year mortality from 3% to 2% in patients undergoing CABG (either with or without cardiopulmonary bypass).
The results of this study can support the use of volatile agents in all CABG procedures worldwide (more than 500.000 per year) with 2.500 lives saved per year (in the hypothesis that nowadays half the procedures are performed with a TIVA and that 1 year mortality can be reduced from 3% to 2% using volatile agents).
|Condition or disease||Intervention/treatment||Phase|
|Aortocoronary Bypass Cardiac Surgery Coronary Artery Bypass Grafting||Drug: desflurane, isoflurane, sevoflurane Drug: total intravenous anesthetics||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Volatile Anesthetics to Reduce Mortality in Cardiac Surgery: A Multicentre Randomized Controlled Study|
|Actual Study Start Date :||April 14, 2014|
|Actual Primary Completion Date :||October 2017|
|Actual Study Completion Date :||September 2018|
|Experimental: volatile anesthetics (desflurane, isoflurane, sevoflurane)||
Drug: desflurane, isoflurane, sevoflurane
|Active Comparator: total intravenous anesthesia||
Drug: total intravenous anesthetics
- mortality [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02105610
|Study Chair:||alberto zangrillo, Prof||Vita-Salute University of Milano|